- Report
- October 2024
- 188 Pages
Global
From €3181EUR$3,545USD£2,738GBP
€3534EUR$3,939USD£3,042GBP
- Report
- October 2024
- 199 Pages
Global
From €3181EUR$3,545USD£2,738GBP
€3534EUR$3,939USD£3,042GBP
- Report
- December 2024
- 100 Pages
Global
From €5339EUR$5,950USD£4,595GBP
- Report
- February 2025
- 200 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- April 2025
- 200 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- April 2025
- 200 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- March 2025
- 200 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- March 2025
- 175 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- July 2024
- 146 Pages
Global
From €2691EUR$2,999USD£2,316GBP
- Report
- July 2024
- 150 Pages
Global
From €3365EUR$3,750USD£2,896GBP
- Report
- September 2024
- 183 Pages
Global
From €4038EUR$4,500USD£3,475GBP
- Report
- April 2021
- 150 Pages
Asia Pacific
From €3096EUR$3,450USD£2,664GBP
- Report
- February 2024
- 120 Pages
Global
From €4262EUR$4,750USD£3,668GBP
- Report
- November 2022
- 76 Pages
Global
From €1795EUR$2,000USD£1,545GBP
- Report
- April 2025
- 50 Pages
Global
From €2378EUR$2,650USD£2,047GBP

Famotidine is a medication used to treat gastrointestinal disorders, such as acid reflux and ulcers. It is a histamine-2 receptor antagonist, which works by reducing the amount of acid produced in the stomach. It is available in both prescription and over-the-counter forms. Famotidine is commonly used to treat symptoms of gastroesophageal reflux disease (GERD), peptic ulcers, and other conditions caused by excess stomach acid. It is also used to prevent and treat ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs).
Famotidine is a widely used drug in the gastrointestinal market. It is one of the most commonly prescribed medications for GERD and other acid-related disorders. It is also used to treat and prevent ulcers caused by NSAIDs. Famotidine is generally well-tolerated and has few side effects.
Some companies in the Famotidine market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. Show Less Read more